Highlights Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 05:10:08 21/01/2026 GMT			5-day change	1st Jan Change
2.500 ^AUD	-1.57%		-6.37%	-8.09%

01-19	Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of A Biologics License Application for Its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain	CI
01-19	Mesoblast Says FDA Acknowledges Potential Efficacy of Cell Therapy Product	MT

Highlights

01-19	Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of A Biologics License Application for Its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain	CI
01-19	Mesoblast Says FDA Acknowledges Potential Efficacy of Cell Therapy Product	MT
01-09	Mesoblast says Ryoncil sales for quarter increase 60% to $35.1M	RE
12-30	Sector Update: Health Care Stocks Edge Lower Tuesday Afternoon	MT
12-30	Sector Update: Health Care Stocks Edge Higher Premarket Tuesday	MT
12-30	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Fed Meeting Minutes	MT
12-12	Mesoblast Limited Announces Independent Study Presented at American Society of Hematology Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD	CI
11-25	Mesoblast Limited Provides Revenue Guidance for the Quarter Ending December 31, 2025	CI
11-20	Mesoblast And BMT CTN Initiate Pivotal Trial Of Ryoncil For Severe Acute GVHD In Adults	CI
11-17	Mesoblast Limited Appoints James M. O?Brien as Chief Financial Officer	CI
11-05	Mesoblast Limited to Meet with FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation	CI
11-05	Mesoblast to meet with FDA next month to discuss rexlemestrocel-L and opioid cessation	RE
20/10/25	Mesoblast posts quarter revenue from cell therapy products $20.6 million	RE
13/10/25	Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says	MT
07/10/25	Mesoblast Ltd posts gross revenue of $21.9 million on Ryoncil sales for quarter	RE
03/10/25	Mesoblast Limited Receives J-Code from Medicare & Medicaid Services Facilitating Reimbursement and Broader Patient Access	CI
26/09/25	Mesoblast Limited Announces its Allogeneic Cell Therapy Products Are Designated U.S. Country of Origin	CI
15/09/25	Mesoblast Limited Announces Successful Commercial Launch of Ryoncil	CI
15/09/25	Mesoblast Launches FDA-Approved Ryoncil at Global Healthcare Conferences	MT
29/08/25	Mesoblast Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
28/08/25	Mesoblast Posts Narrower Fiscal 2025 Loss, Higher Revenue	MT
01/07/25	Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure	CI
01/07/25	Mesoblast Aligns with FDA on Biologics License Application Requirements for Ischemic Heart Failure Drug Candidate, Shares Rise 6%	MT
12/06/25	Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD	CI
16/05/25	Cynata Therapeutics Says Potential Approval of CYP-001 Drug Candidate Unimpeded, Shares Jump 6%	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Highlights

Filters